Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ARVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Arvinas, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arvinas, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How ARVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-04 | ARV-6723 | Pre-clinical data presentation | Pre-clinical |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ARV-6723 Small MoleculesNCT07749586 | Advanced Solid Tumor | Phase 1/2 | RECRUITING | 499 | Mar 31, 2032 | ||||||
| ARV-393 Small MoleculesNCT06393738 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Phase 1 | RECRUITING | 329 | Mar 1, 2028 | ||||||
| ARV-110 Small MoleculesCompletedNCT03888612 | Prostate Cancer Metastatic | Phase 1/2 | COMPLETED | 248 | Jan 27, 2025 | ||||||
| Bavdegalutamide Small MoleculesCompletedNCT05177042 | Prostate Cancer Metastatic | Phase 1 | COMPLETED | 45 | Apr 10, 2025 | ||||||
| ARV-806 Gene TherapiesNCT07023731 | KRAS G12D Mutation | Phase 1/2 | COMPLETED | 76 | Oct 30, 2026 | ||||||
| ARV-471 in combination with Everolimus Small MoleculesMarketedNCT05501769 | Breast Cancer | Approved | COMPLETED | 184 | Aug 25, 2025 | ||||||
| Vepdegestrant Small MoleculesMarketedNCT04072952 | Breast Cancer | Approved | COMPLETED | 219 | Mar 5, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ARV-102 | Parkinson's disease | Phase 1 | 2026-03-18 | greater than 50% LRRK2 degradation in the CSF; approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid (CSF) at all doses by day 14; maintained the reduction through day 28Read More | Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 DaysRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Loomis David KOfficer (VP, Chief Accounting Officer) | Sell | -232 39,961 held | $6.36 | 11/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0.6 % (-62.5 %) | 15.86 M | 2.05 M | 225.4% ( 1.42 M) |
Ownership Trends
ARVN Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How ARVN ranks across every disease it competes in
ARVN News
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas, Inc. will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18. The company is known for its innovative protein degradation therapies and has multiple investigational drugs in clinical trials. Arvinas recently achieved FDA approval for its first PROTAC drug, developed in partnership with Pfizer.
Read more →Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
Arvinas announced that preliminary clinical data for ARV-393 (zaloblideg) will be presented at the 2026 ASH Annual Meeting. The data will cover safety, pharmacokinetics, and preliminary efficacy in patients with relapsed/refractory non-Hodgkin lymphoma. ARV-393 specifically targets the BCL6 protein, implicated in various lymphomas.
Read more →Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Arvinas reported its third quarter 2026 financial results, highlighting the initiation of dosing in a Phase 1/2 trial of ARV-6723. The company reaffirmed its commitment to share clinical data from several ongoing trials in late 2026 and 2027. Additionally, ARV-102 showed promising results in Parkinson's disease during a recent conference presentation.
Read more →Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Arvinas has reinstated the Early Career Researcher Award to honor innovative research in targeted protein degradation. The award, which includes a $25,000 prize, aims to support emerging scientists and will accept nominations from November 1 to December 31, 2026. The winner will be recognized in mid-2027.
Read more →Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Arvinas, Inc. will report its third quarter 2026 financial results on November 3, 2026. The live webcast will begin at 8:00 a.m. ET, accessible via the investor page on their website. The company is known for its innovative protein degradation therapies and has several investigational drugs in clinical development.
Read more →Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Arvinas, Inc. presented promising data from a Phase 1 clinical trial of ARV-102 for Parkinson's disease, showing improvements in eye movement and biomarker correlations. The trial indicated that ARV-102 effectively targets LRRK2, relevant to neurodegenerative diseases. The findings support further clinical evaluation of ARV-102, despite the study not being designed to assess clinical efficacy.
Read more →Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas, Inc. announced that it will present novel biomarker data from its Phase 1 clinical trial of ARV-102 at the 2026 International Congress of Parkinson's Disease and Movement Disorders. The investigational drug targets LRRK2, a protein implicated in Parkinson's disease. Presentations will occur both as oral and e-poster sessions during the congress in Seoul, Korea.
Read more →Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas, Inc. has announced the granting of stock options and restricted stock units to a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term with an exercise price matching the stock's closing price on the grant date. Arvinas continues to develop innovative therapies through its PROTAC platform, targeting various diseases.
Read more →Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Arvinas, Inc. has announced the dosing of the first patient in its Phase 1/2 clinical trial for ARV-6723, an oral PROTAC targeting HPK1 in advanced solid tumors. This marks Arvinas' first entry into immuno-oncology. Preclinical studies showed promising results, indicating ARV-6723's potential to enhance immune activity and address resistance to existing therapies. The trial will evaluate safety and preliminary antitumor activity.
Read more →Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference. The company is focused on developing therapies using its PROTAC platform, which targets disease-causing proteins. Arvinas is advancing multiple investigational drugs for various conditions, highlighting its commitment to innovation in biotechnology.
Read more →Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arvinas, Inc. reported strong financial results for Q2 2026, highlighted by the FDA's approval of VEPPANU, the first PROTAC therapy. The company has successfully licensed VEPPANU to Rigel Pharmaceuticals and anticipates sharing clinical data from three Phase 1 programs within the next year. Additionally, promising preclinical data was presented for the HPK1 degrader program, ARV-6723.
Read more →Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
Arvinas, Inc. will report its second quarter 2026 financial results on August 4, 2026, during a live webcast. The event will include a corporate update and can be accessed via the company's investor page. Arvinas is known for its innovative PROTAC platform, which targets disease-causing proteins for degradation.
Read more →Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Arvinas, Inc. has joined the LRRK2 Investigative Therapeutics Exchange (LITE) and the Parkinson’s Precision Medicine Initiative (PPMI), programs supported by The Michael J. Fox Foundation. This collaboration aims to advance ARV-102, Arvinas’ investigational treatment targeting LRRK2 for conditions like Parkinson's disease. The initiatives will focus on enhancing understanding of LRRK2 biology and accelerating the development of targeted therapies. Arvinas has a commitment to improving treatments for neurodegenerative diseases through innovative research.
Read more →Arvinas to Present at Jefferies Global Healthcare Conference 2026
Arvinas, Inc. will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company is known for its innovative drug development using targeted protein degradation. They have successfully developed the first FDA-approved PROTAC for treating advanced breast cancer and are advancing multiple investigational drugs for various diseases.
Read more →Arvinas Employees Give Back During Company-wide Impact Day
Arvinas, a clinical-stage biotechnology company, celebrated its fourth Company-wide Impact Day, where employees engaged in various community service activities across multiple locations. The company emphasizes its commitment to both patients and the communities where it operates. This year's initiatives included preparing meals for patients, creating comforting blankets, and beautifying local spaces. The event demonstrates Arvinas' dedication to making a positive impact. CEO Randy Teel expressed pride in the employees' passion for community service.
Read more →Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
Arvinas and Pfizer have entered into a license agreement with Rigel Pharmaceuticals for the exclusive global rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC therapy for certain types of breast cancer. The agreement includes an initial payment of $85 million, with opportunities for additional payments based on development milestones. Rigel will handle commercialization in the U.S., while Arvinas and Pfizer will continue their development efforts. The transaction is subject to necessary regulatory approvals, which could delay the implementation of their plans.
Read more →Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arvinas, Inc. reported its first quarter 2026 financial results and corporate updates, highlighting significant developments including the FDA approval of VEPPANU, a groundbreaking PROTAC for advanced breast cancer. The approval marks a milestone as it is the first of its kind, correlating with Arvinas' long-term focus on targeted protein degradation. Additionally, Phase 1 clinical trials show encouraging results for other drug candidates like ARV-102 for Parkinson's disease. Arvinas is also expanding collaborations and planning further trials, reinforcing its growth trajectory in the biotechnology sector.
Read more →Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Arvinas, Inc. will report its first quarter 2026 financial results and provide a corporate update on May 12, 2026. The live webcast will begin at 8:00 a.m. ET and will be accessible on the company's investor page. Arvinas is known for its innovative protein degradation therapies and has made significant advancements in treating various cancers and neurodegenerative disorders.
Read more →